Article
Pembrolizumab Expanded to Treat Relapsed, Refractory cHL in Adults, Children
Rating:
0.0
Views:
71
Likes:
1
Library:
1
It is the first PD-1 inhibitor to be approved to be used as a monotherapy for the treatment of adult and pediatric patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL).
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value